Welcome to MetonChem!
Bioactive molecules >
PF-04971729 (Ertugliflozin) is a potent and selective inhibitor of the sodium-dependent glucose cotransporter 2 and clinical candidate for the treatment of type 2 diabetes mellitus.
AMG-3969 is a potent glucokinase-glucokinase regulatory protein interaction (GK-GKRP) disruptor with an IC50 of 4 nM. AMG-3969 potently induced the dissociation of the GK-GKRP complex ...
LY-333531 (Ruboxistaurin) is a PKC beta inhibitor potentially for the treatment of diabetic nephropathy and diabetic macular edema.
Ruboxistaurin (LY-333531) is a PKC beta inhibitor potentially for the treatment of diabetic nephropathy and diabetic macular edema.
ZLN005 is a novel transcriptional regulator of peroxisome proliferator-activated receptor-γ coactivator-1α (PGC-1α).
APD668 (JNJ-28630368) is a potent GPR119 agonist with EC50 of 2.7 nM and 33 nM for hGPR119 and ratGPR119 respectively.
Omarigliptin (MK-3102) is a potent and long-acting DPP-4 inhibitor for once-weekly treatment of type 2 diabetes.
Teneligliptin is a novel, potent, and long-lasting dipeptidyl peptidase-4 inhibitor; competitively inhibited human plasma, rat plasma, and human recombinant DPP-4 in vitro, with IC50 values of approximately 1 nM.
Fasiglifam (TAK-875) is a potent, selective, and orally bioavailable GPR40 agonist, with a pharmacokinetic profile enabling long-acting drug efficacy.
Empagliflozin (BI10773) is an inhibitor of the sodium glucose co-transporter-2 (SGLT-2), and causes sugar in the blood to be absorbed by the kidneys and eliminated in urine.
Trelagliptin (SYR-472) is a long acting dipeptidyl peptidase-4 (DPP-4) inhibitor that is being developed by Takeda for the treatment of type 2 diabetes (T2D).
Dutogliptin (PHX1149) is a selective and orally active DPP4 inhibitor. Dutogliptin improves glycaemic control in patients with type 2 diabetes. PP-4 inhibitors or gliptins, are a class of oral hypoglycemics that block DPP-4.
Linagliptin (BI-1356) is a DPP-4 inhibitor developed by Boehringer Ingelheim for treatment of type II diabetes. Linagliptin was approved by the US FDA on 2 May 2011 for treatment of type II diabetes.
Dapagliflozin (BMS-512148) is a drug used to treat type 2 diabetes approved in 2012 by FDA. Dapagliflozin inhibits subtype 2 of the sodium-glucose transport proteins (SGLT2) which are responsible for at least 90% of the glucose reabsorption in the kidney.
Alogliptin (Nesina; SYR-322) is a potent, selective inhibitor of DPP-4 with IC50 of <10 nM, exhibits greater than 10,000-fold selectivity over DPP-8 and DPP-9.
Alogliptin (SYR 322) benzoate is a potent, selective inhibitor of DPP-4 with IC50 of <10 nM, exhibits greater than 10,000-fold selectivity over DPP-8 and DPP-9.
Teneligliptin (hydrobromide) is a novel, potent, and long-lasting dipeptidyl peptidase-4 inhibitor; competitively inhibited human plasma, rat plasma, and human recombinant DPP-4 in vitro, with IC50 values of approximately 1 nM.
Canagliflozin (JNJ 24831754ZAE) is a drug for the treatment of type 2 diabetes, which is an inhibitor of subtype 2 sodium-glucose transport protein (SGLT2).
Ipragliflozin is an orally active, next-generation sodium-glucose transporter 2 (SGLT2) inhibitor, has been developed by Astellas Pharma and Kotobuki Pharmaceutical for the treatment of type 2 diabetes mellitus.
Aloxistatin is an inhibitor of cysteine protease with blood platelet aggregation inhibiting activity, which is also an irreversible, membrane-permeable inhibitor of lysosomal and cytosolic cysteine proteases with the ability to inhibit calpain activity in intact platelets.
Cas#, Product Name